awt020
Recombinant proteinexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Sep 15, 2023 (NCT06092580)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Programmed cell death protein 1INHIBITOR
PDCD1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06839105 | Phase 1 | Feb 14, 2025 | Shanghai Junshi Bioscience Co.,Ltd. |
| NCT06092580 | Phase 1 | Sep 15, 2023 | Anwita Biosciences, Icon Cancer Center |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Anwita Biosciences | For profit | 1 | 1 | 1 | 2023 |
| Icon Cancer Center | Academic/Hospital | 1 | 0 | 1 | 2023 |
| Shanghai Junshi Bioscience Co.,Ltd. | For profit | 1 | 1 | 1 | 2025 |
3 organizations
Page 1 / 1